NASDAQ:INVA Innoviva Q3 2025 Earnings Report $20.50 -0.05 (-0.24%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$20.42 -0.09 (-0.41%) As of 10/2/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Innoviva EPS ResultsActual EPS$1.08Consensus EPS $0.46Beat/MissBeat by +$0.62One Year Ago EPSN/AInnoviva Revenue ResultsActual Revenue$107.80 millionExpected Revenue$91.31 millionBeat/MissBeat by +$16.50 millionYoY Revenue GrowthN/AInnoviva Announcement DetailsQuarterQ3 2025Date11/5/2025TimeBefore Market OpensConference Call DateWednesday, November 5, 2025Conference Call Time4:00PM ETUpcoming EarningsInnoviva's Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 5, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K) Innoviva Earnings HeadlinesZymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma DealSeptember 28, 2026 | benzinga.comInnoviva (NASDAQ:INVA) Stock Picked Up by Analysts at OppenheimerSeptember 25, 2026 | americanbankingnews.comA new type of AI could unleash gains of up to 10,000%A new AI category called Accelerated AI is starting to gain traction, and most investors haven't caught on yet. Early movers in past technology shifts have seen outsized results, and this emerging niche is drawing comparisons. Get the name and ticker of the leading Accelerated AI company making waves right now.October 4 at 1:00 AM | Brownstone Research (Ad)Theravance Biopharma Completes Merger and Plans Nasdaq DelistingSeptember 23, 2026 | tipranks.comZymeworks Closes Theravance Acquisition and CVR FinancingSeptember 23, 2026 | tipranks.comOppenheimer Upgrades Innoviva to Outperform From Neutral, $35 Price TargetSeptember 23, 2026 | marketscreener.comMSee More Innoviva Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Innoviva? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Innoviva and other key companies, straight to your email. Email Address About InnovivaInnoviva (NASDAQ:INVA) is a healthcare company focused on acquiring, developing and commercializing pharmaceutical assets, with a particular emphasis on medicines for respiratory and infectious diseases. The company generates a substantial portion of its business through royalty interests in marketed products and also invests in healthcare companies and development-stage therapies. Innoviva holds royalty rights related to several respiratory medicines developed in collaboration with GlaxoSmithKline, including Trelegy Ellipta, Anoro Ellipta and Breo Ellipta, which is marketed as Relvar Ellipta in some international markets. These inhaled therapies are used to treat conditions such as chronic obstructive pulmonary disease and asthma. Innoviva has also held interests in other respiratory and anti-infective products through licensing arrangements and corporate investments. The company was formerly known as Theravance, Inc. and adopted the Innoviva name in 2016 following the separation of its operations from Theravance Biopharma. Based in Burlingame, California, Innoviva serves international healthcare markets through its licensing partnerships, royalty agreements and portfolio companies. Its activities include supporting the development and commercialization of medicines while seeking additional opportunities in biopharmaceuticals.View Innoviva ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/28 - 10/02Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street DividedMcCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense Revenue Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
